Shiqi Peng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8459218/publications.pdf

Version: 2024-02-01

63	943	516710 16	501196 28
papers	citations	h-index	g-index

87	87	87	1175
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis and cytotoxic activities of Î²-carboline amino acid ester conjugates. Bioorganic and Medicinal Chemistry, 2006, 14, 6998-7010.	3.0	102
2	Novel N-(3-carboxyl-9-benzyl-Î²-carboline-1-yl)ethylamino acids: Synthesis, anti-tumor evaluation, intercalating determination, 3D QSAR analysis and docking investigation. European Journal of Medicinal Chemistry, 2009, 44, 4153-4161.	5.5	85
3	A class of oral N-[(1S,3S)-1-methyl-1,2,3,4-tetrahydro-Î²-carboline-3-carbonyl]-Nâ€²-(amino-acid-acyl)hydrazine: Discovery, synthesis, inÂvitro anti-platelet aggregation/inÂvivo anti-thrombotic evaluation and 3D QSAR analysis. European Journal of Medicinal Chemistry, 2011, 46, 3237-3249.	5.5	43
4	Nanosized Aspirin-Arg-Gly-Asp-Val: Delivery of Aspirin to Thrombus by the Target Carrier Arg-Gly-Asp-Val Tetrapeptide. ACS Nano, 2013, 7, 7664-7673.	14.6	41
5	Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity. Bioorganic and Medicinal Chemistry, 2006, 14, 4761-4774.	3.0	40
6	Lipid rafts-mediated endocytosis and physiology-based cell membrane traffic models of doxorubicin liposomes. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 1801-1811.	2.6	38
7	Implications for blood-brain-barrier permeability, in vitro oxidative stress and neurotoxicity potential induced by mesoporous silica nanoparticles: effects of surface modification. RSC Advances, 2016, 6, 2800-2809.	3.6	30
8	A new class of anti-thrombosis hexahydropyrazino-[1â€²,2â€²:1,6]pyrido-[3,4-b]-indole-1,4-dions: Design, synthesis, logK determination, and QSAR analysis. Bioorganic and Medicinal Chemistry, 2007, 15, 5672-5693.	3.0	29
9	A Class of 3S-2-Aminoacyltetrahydro-Î²-carboline-3-carboxylic Acids: Their Facile Synthesis, Inhibition for Platelet Activation, and High in Vivo Anti-Thrombotic Potency. Journal of Medicinal Chemistry, 2010, 53, 3106-3116.	6.4	28
10	A class of novel N-(3S-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-l-amino acid derivatives: their synthesis, anti-thrombotic activity evaluation, and 3D QSAR analysis. European Journal of Medicinal Chemistry, 2009, 44, 4904-4919.	5.5	27
11	A class of novel Schiffâ€™s bases: Synthesis, therapeutic action for chronic pain, anti-inflammation and 3D QSAR analysis. Bioorganic and Medicinal Chemistry, 2010, 18, 2165-2172.	3.0	25
12	A class of novel carboline intercalators: Their synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and 3D QSAR analysis. Bioorganic and Medicinal Chemistry, 2010, 18, 6220-6229.	3.0	25
13	In vitro inhibition of fatty acid synthase by 1,2,3,4,6-penta-O-galloyl-Î²-d-glucose plays a vital role in anti-tumour activity. Biochemical and Biophysical Research Communications, 2014, 445, 346-351.	2.1	25
14	A class of novel N-(1-methyl-Î²-carboline-3-carbonyl)-Nâ€²-(aminoacid-acyl)-hydrazines: Aromatization leaded design, synthesis, in vitro anti-platelet aggregation/in vivo anti-thrombotic evaluation and 3D QSAR analysis. European Journal of Medicinal Chemistry, 2011, 46, 5598-5608.	5.5	24
15	Novel N-(3-carboxyl-9-benzylcarboline-1-yl)ethylamino acids: synthesis, anti-proliferation activity and two-step-course of intercalation with calf thymus DNA. Molecular BioSystems, 2007, 3, 855.	2.9	22
16	2,3-Diamino acid modifying 3S-tetrahydroisoquinoline-3-carboxylic acids: Leading to a class of novel agents with highly unfolded conformation, selective in vitro anti-platelet aggregation and potent in vivo anti-thrombotic activity. Bioorganic and Medicinal Chemistry, 2010, 18, 1536-1554.	3.0	20
17	Preparation and Characterization of RGDS/Nanodiamond as a Vector for VEGF-siRNA Delivery. Journal of Biomedical Nanotechnology, 2015, 11, 70-80.	1.1	16
18	Loading cisplatin onto 6-mercaptopurine covalently modified MSNS: a nanomedicine strategy to improve the outcome of cisplatin therapy. Drug Design, Development and Therapy, 2016, Volume 10, 3933-3946.	4.3	16

#	Article	IF	Citations
19	Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. European Journal of Clinical Pharmacology, 2016, 72, 1195-1204.	1.9	16
20	A class of Trp-Trp-AA-OBzl: Synthesis, inÂvitro anti-proliferation/inÂvivo anti-tumor evaluation, intercalation-mechanism investigation and 3D QSAR analysis. European Journal of Medicinal Chemistry, 2011, 46, 3410-3419.	5.5	15
21	Aqueous extract of Rabdosia rubescens leaves: forming nanoparticles, targeting P-selectin, and inhibiting thrombosis. International Journal of Nanomedicine, 2015, 10, 6905.	6.7	14
22	RGD-peptides modifying dexamethasone: to enhance the anti-inflammatory efficacy and limit the risk of osteoporosis. MedChemComm, 2015, 6, 1345-1351.	3.4	14
23	RGDS covalently surfaced nanodiamond as a tumor targeting carrier of VEGF-siRNA: synthesis, characterization and bioassay. Journal of Materials Chemistry B, 2015, 3, 9260-9268.	5.8	13
24	Cu2+-RGDFRGDS: exploring the mechanism and high efficacy of the nanoparticle in antithrombotic therapy. International Journal of Nanomedicine, 2015, 10, 2925.	6.7	11
25	BPIC: A novel anti-tumor lead capable of inhibiting inflammation and scavenging free radicals. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1146-1150.	2.2	11
26	Design, synthesis, and testing of an isoquinoline-3-carboxylic-based novel anti-tumor lead. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4434-4436.	2.2	11
27	Tetrahydro-Î²-carboline-3-carboxyl-thymopentin: a nano-conjugate for releasing pharmacophores to treat tumor and complications. Journal of Materials Chemistry B, 2016, 4, 1384-1397.	5.8	11
28	Synthesis, nano-features, ex vivo anti-platelet aggregation and in vivo antithrombotic activities of poly-Î±,Î²-<scp>dl</scp>-aspartyl-<scp>l</scp>-arginine. MedChemComm, 2012, 3, 102-108.	3.4	10
29	Novel nano-materials, RGD-tetrapeptide-modified 17Î²-amino-11Î±-hydroxyandrost-1,4-diene-3-one: synthesis, self-assembly based nano-images and in vivo anti-osteoporosis evaluation. Journal of Materials Chemistry, 2012, 22, 4652.	6.7	10
30	IQCA-TASS: a nano-scaled P-selectin inhibitor capable of targeting thrombus and releasing IQCA/TARGD(S)S in vivo. Journal of Materials Chemistry B, 2017, 5, 917-927.	5.8	10
31	Self-complexation and complexation-controlled target cancer therapy. MedChemComm, 2012, 3, 1059.	3.4	9
32	The application of tetrahydroisoquinoline-3-carbonyl-TARGD(F)F as an anti-thrombotic agent having dual mechanisms of action. Molecular BioSystems, 2012, 8, 2672.	2.9	9
33	Nano-scaled MTCA-KKV: for targeting thrombus, releasing pharmacophores, inhibiting thrombosis and dissolving blood clots in vivo . International Journal of Nanomedicine, 2019, Volume 14, 4817-4831.	6.7	9
34	Development of three-component conjugates: to get nano-globes with porous surfaces, high in vivo anti-osteoporosis activity and minimal side effects. Journal of Materials Chemistry, 2012, 22, 21740.	6.7	8
35	DHDMIQK(KAP): a novel nano-delivery system of dihydroxyl-tetrahydro-isoquinoline-3-carboxylic acid and KPAK towards the thrombus. Journal of Materials Chemistry B, 2016, 4, 5991-6003.	5.8	8
36	A novel lead of P-selectin inhibitor: Discovery, synthesis, bioassays and action mechanism. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4631-4636.	2.2	8

#	Article	IF	Citations
37	Docking of THPDTPI: to explore P-selectin as a common target of anti-tumor, anti-thrombotic and anti-inflammatory agent. Oncotarget, 2018, 9, 268-281.	1.8	8
38	Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA. International Journal of Nanomedicine, 2018, Volume 13, 1139-1158.	6.7	8
39	RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine . International Journal of Nanomedicine, 2019, Volume 14, 7263-7279.	6.7	8
40	Small molecule PZL318: forming fluorescent nanoparticles capable of tracing their interactions with cancer cells and activated platelets, slowing tumor growth and inhibiting thrombosis. International Journal of Nanomedicine, 2015, 10, 5273.	6.7	7
41	Design and development of ICCA as a dual inhibitor of GPIIb/IIIa and P-selectin receptors. Drug Design, Development and Therapy, 2018, Volume 12, 2097-2110.	4.3	7
42	Energy minimized crystal structures of P-selectins based on molecular dynamics simulation: leading to two average structures capable of designing anti-thrombotic agents. MedChemComm, 2013, 4, 1066.	3.4	6
43	N-(3-hydroxymethyl-β-carboline-1-yl-ethyl-2-yl)-L-Phe: development toward a nanoscaled antitumor drug capable of treating complicated thrombosis and inflammation. Drug Design, Development and Therapy, 2017, Volume11, 225-239.	4.3	6
44	5-(Bis(3-(2-hydroxyethyl)-1H-indol-2-yl)methyl)-2-hydroxybenzoic acid (BHIMHA): showing a strategy of designing drug to block lung metastasis of tumors. Drug Design, Development and Therapy, 2016, 10, 711.	4.3	5
45	Discovery of DEBIC to correlate P-selectin inhibition and DNA intercalation in cancer therapy and complicated thrombosis. Oncotarget, 2018, 9, 32119-32133.	1.8	5
46	13-[CH2CO-Cys-(Bzl)-OBzl]-Berberine: Exploring The Correlation Of Anti-Tumor Efficacy With ROS And Apoptosis Protein . OncoTargets and Therapy, 2019, Volume 12, 10651-10662.	2.0	5
47	Modifying ICCA with Trp-Phe-Phe to Enhance in vivo Activity and Form Nano-Medicine . International Journal of Nanomedicine, 2020, Volume 15, 465-481.	6.7	5
48	N-[2(3-Carboxyl-9-benzyl-carboline-1-yl)ethyl-1-yl]-amino acids: correlation of spectral property with in vivo anti-tumor activity. Medicinal Chemistry Research, 2012, 21, 116-123.	2.4	4
49	RGD(F/S/V)-Dex: towards the development of novel, effective, and safe glucocorticoids. Drug Design, Development and Therapy, 2016, 10, 1059.	4.3	4
50	Docking based design of diastereoisomeric MTCA as GPIIb/IIIa receptor inhibitor. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5114-5118.	2.2	4
51	Dimethyl 2,2′-[2,2′-(ethane-1,1-diyl)bis(1H-indole-3,2-diyl)]-diacetate: a small molecule capable of nano-scale assembly, inhibiting venous thrombosis and inducing no bleeding side effect. International Journal of Nanomedicine, 2018, Volume 13, 7835-7844.	6.7	4
52	Development of 13-Cys-BBR as an Agent Having Dual Action of Anti-Thrombosis and Anti-Inflammation . Drug Design, Development and Therapy, 2020, Volume 14, 2187-2197.	4.3	4
53	A class of novel AA-Trp-Trp-OBzl: synthesis, in vitro anti-proliferation, in vivo anti-tumor action, and intercalation mechanism. MedChemComm, 2011, 2, 126-131.	3.4	3
54	ATIQCTPC: a nanomedicine capable of targeting tumor and blocking thrombosis in vivo. International Journal of Nanomedicine, 2017, Volume 12, 4415-4431.	6.7	3

#	Article	IF	Citations
55	Design, synthesis, and in vivo evaluations of benzyl N^{ï‰}-nitro-N^{Î±}-(9H-pyrido[3,4-b]indole-3-carbonyl)-<scp>l</scp>-argininate as an apoptosis inducer capable of decreasing the serum concentration of P-selectin. MedChemComm, 2016, 7, 1730-1737.	3.4	2
56	Heptapeptide-based modification leading to enhancing the action of MTCA on activated platelets, P-selectin, GPIIb/IIIa. Future Medicinal Chemistry, 2018, 10, 1957-1970.	2.3	2
57	BCESA: a nano-scaled intercalator capable of targeting tumor tissue and releasing anti-tumoral β-carboline-3-carboxylic acid . International Journal of Nanomedicine, 2019, Volume 14, 3027-3041.	6.7	2
58	Exploring the action of RGDV-gemcitabine on tumor metastasis, tumor growth and possible action pathway. Scientific Reports, 2020, 10, 15729.	3.3	2
59	Mechanism of forming trimer, self-assembling nano-particle and inhibiting tumor growth of small molecule CIPPCT. MedChemComm, 2014, 5, 1634-1643.	3.4	1
60	Modifying tetramethyl–nitrophenyl–imidazoline with amino acids: design, synthesis, and 3D-QSAR for improving inflammatory pain therapy. Drug Design, Development and Therapy, 2015, 9, 2329.	4.3	1
61	Discovery of novel (6S/12aS)-heptachpyridone capable of inhibiting thrombosis in vivo. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127440.	2.2	1
62	ATIQCTPC targeting MMP-9: a key step to slowing primary tumor growth and inhibiting metastasis of lewis lung carcinoma in vivo. Oncotarget, 2017, 8, 63881-63889.	1.8	1
63	Cholyl-l-lysine-carboxylbutyryl adriamycin prodrugs targeting chemically induced liver injury. Journal of Materials Chemistry B, 2017, 5, 470-478.	5.8	0